Form 8-K - Current report:
SEC Accession No. 0001193125-13-239704
Filing Date
2013-05-29
Accepted
2013-05-29 17:17:56
Documents
5
Period of Report
2013-05-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.03: Material Modifications to Rights of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d545611d8k.htm 8-K 33112
2 EX-4.1 d545611dex41.htm EX-4.1 309552
3 EX-10.1 d545611dex101.htm EX-10.1 9530
4 EX-99.1 d545611dex991.htm EX-99.1 8930
5 GRAPHIC g545611g83w44.jpg GRAPHIC 11267
  Complete submission text file 0001193125-13-239704.txt   378033
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 4152444990
TITAN PHARMACEUTICALS INC (Filer) CIK: 0000910267 (see all company filings)

EIN.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-27436 | Film No.: 13879071
SIC: 2836 Biological Products, (No Diagnostic Substances)